Anemia in Heart Failure: Pathophysiology, Pathogenesis, Treatment, and Incognitae
Authors:
- Carlos CarameloCCCarlos Caramelo
- Soledad JustSJSoledad Just
- Paloma GilPGPaloma Gil
- 1 January 2007
- journal article
- abstracts
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 60 (8) , 848-860
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart FailureJACC, 2006
- Regulation of angiogenesis by hypoxia-inducible factor 1Critical Reviews in Oncology/Hematology, 2006
- Enhanced erythropoiesis mediated by activation of the renin‐angiotensin system via angiotensin II type 1a receptorThe FASEB Journal, 2005
- ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the AdultJACC, 2005
- Differentiating the functional role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α (EPAS‐1) by the use of RNA interference: erythropoietin is a HIF‐2α target gene in Hep3B and Kelly cellsThe FASEB Journal, 2004
- Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trialEuropean Heart Journal, 2004
- Effect of anemia on exercise tolerance in chronic heart failure in menThe American Journal of Cardiology, 2003
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profilesThe American Journal of Cardiology, 1994